Prestige Consumer Healthcare Inc. $PBH Shares Purchased by Tributary Capital Management LLC

Tributary Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 157.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 379,410 shares of the company’s stock after buying an additional 231,969 shares during the period. Tributary Capital Management LLC owned 0.77% of Prestige Consumer Healthcare worth $23,675,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Prestige Consumer Healthcare by 312.5% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter worth about $27,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $46,000. Finally, First Horizon Advisors Inc. raised its position in shares of Prestige Consumer Healthcare by 294.1% in the second quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after buying an additional 447 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $62.76 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The firm has a market capitalization of $3.02 billion, a P/E ratio of 15.57, a P/E/G ratio of 1.97 and a beta of 0.40. The business’s 50-day simple moving average is $60.80 and its 200-day simple moving average is $66.07.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same quarter last year, the firm posted $1.09 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president directly owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

Analyst Upgrades and Downgrades

PBH has been the subject of several recent analyst reports. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Oppenheimer decreased their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).